A Phase 2 interventional study of Pembrolizumab and Azacitidine in Pancreas Cancer, sponsored by Susan E. Bates. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by Susan E. Bates · Phase 2, Interventional, and Treatment
The purpose of this study is to determine the effectiveness of combining immune therapy, pembrolizumab, with a hypomethylating agent, azacitidine, for pancreatic cancer. People who have advanced pancreatic cancer with disease progression on first-line therapy are usually treated with a second chemotherapy regimen. However, there is no single accepted chemotherapy regimen and national guidelines recommend chemotherapy or clinical trial participation. In this study, all study subjects will receive a combination of immune therapy (every 3 weeks) and a hypomethylating agent (every 4 weeks). To date, studies have shown that combining a hypomethylating agent with chemotherapy or immune therapy may benefit patients across different solid tumor types including pancreatic cancer. Preclinical data in a mouse model of pancreatic cancer demonstrates improvement in survival with the combination of a hypomethylating agent and immune therapy. However, the use of single agent hypomethylating agent or immune therapy has not been shown to be effective in patients with pancreatic cancer. The one exception, to date, is the use of immune therapy in those individuals with a particular genetic feature known as mismatch repair deficiency and microsatellite instability. The combination of immune therapy and a hypomethylating agent has not been studied in human subjects and is not approved by the FDA for use in pancreatic cancer.
This is a non-randomized, single-center, open-label trial of pembrolizumab and azacitidine in subjects with locally advanced or metastatic pancreatic adenocarcinoma. Approximately 31 individuals will be asked to participate in this study.
Pancreatic ductal adenocarcinoma (PDA) has the worst prognosis of any major malignancy in the United States and, unlike other common cancers, annual deaths from PDA are rising. Despite recent advances, cytotoxic chemotherapy for PDA has been disappointing. Even among the small subset of patients who are suitable for surgical resection at the time of diagnosis, complete resection is followed by recurrence in majority of patients without further systemic therapy. Thus all PDA patients require systemic chemotherapy and more effective regimens are urgently needed.
Combination chemotherapy is effective in controlling disease and prolonging survival in patients with advanced pancreatic cancer. Despite recent successful phase 3 studies in the first-line setting, there is no defined second-line treatment for patients who experience disease progression following first-line therapy. Consensus guidelines (such as the National Comprehensive Cancer Network (NCCN) guidelines) recommend clinical trial participation in this setting.
The investigators' pre-clinical data suggests that decitabine treatment in the KPC model of pancreatic cancer leads to a significant up-regulation of interferon-related genes and a polarization of the infiltrating immune cells. Based on these results, the investigators have evaluated the effect of single agent decitabine or anti-PD1H (a homologue of PD1 with very similar function and expression pattern) compared to combination therapy (treatment with decitabine followed by PD1H blockade). The investigators' preliminary results showed minimal effect of either agent alone on tumor growth but marked decrease in tumor progression in the combination arm. These results form the foundation of this phase II study.
This study will treat patients with the combination of azacitidine and pembrolizumab. A direct comparison between azacitidine and decitabine in terms of efficacy within a controlled clinical trial has not been performed thus far. In randomized myelodysplastic syndrome (MDS) trials, the remission rates were similar for azacitidine and decitabine but the overall survival in the experimental arm was significantly shorter in the decitabine trial compared to the azacitidine trial. A primary reason to utilize azacitidine in this setting is our desire to amply reduced dose therapy with the goal of maintaining subjects on therapy Low-dose azacitidine is being tested in phase I/II clinical trials for advanced solid tumors-mainly colorectal cancer, small-cell lung carcinomas, ovarian cancer, and breast cancer.
Exclusion Criteria:
Patients with advanced pancreatic cancer will receive pembrolizumab with the hypomethylating agent azacitidine.
Drug: Pembrolizumab · Drug: Azacitidine
Pembrolizumab 200 mg IV every 3 weeks until progression
Also known as: Keytruda
50 mg/m2 subcutaneous daily for 5 days every 28 days
Also known as: Vidaza
Progression-Free Survival (PFS)
PFS is defined as the time from the first day of trial treatment to the first documented disease progression per RECIST 1.1 (At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)) or death due to any cause, whichever occurs first.
Time frame: 24 months
Objective Response Rate (ORR)
ORR is defined as the percentage of the participants in the analysis population who have a complete response (CR) or partial response (PR). Responses are based on assessments per RECIST 1.1.
Time frame: Throughout study duration, up to approx 80 months
Duration of Response (DOR)
For subjects who demonstrate CR or PR, based on assessments per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.
Time frame: Throughout study duration, up to approx 80 months
Disease Control Rate (DCR)
DCR is defined as the percentage of participants who have achieved CR, PR, or stable disease (SD) based on assessments per RECIST 1.1.
Time frame: Throughout study duration, up to approx 80 months
| Milestone | Pembrolizumab |
|---|---|
| Started | 36 |
| Completed | 2 |
| Not completed | 34 |
| Withdrew: Death | 2 |
| Withdrew: Physician decision | 1 |
| Withdrew: Disease progression | 28 |
| Withdrew: Adverse event | 1 |
| Withdrew: Off study prior to treatment | 2 |
PFS is defined as the time from the first day of trial treatment to the first documented disease progression per RECIST 1.1 (At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)) or death due to any cause, whichever occurs first.
| months | Pembrolizumab |
|---|---|
| Progression-Free Survival (PFS) | 1.49 (1.38 to 1.74) |
ORR is defined as the percentage of the participants in the analysis population who have a complete response (CR) or partial response (PR). Responses are based on assessments per RECIST 1.1.
| percentage of participants | Pembrolizumab |
|---|---|
| Objective Response Rate (ORR) | 9.7 |
For subjects who demonstrate CR or PR, based on assessments per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.
| days | Pembrolizumab |
|---|---|
| Patient 1 | 2274 |
| Patient 2 | 881 |
| Patient 3 | 28 |
DCR is defined as the percentage of participants who have achieved CR, PR, or stable disease (SD) based on assessments per RECIST 1.1.
| percentage of participants | Pembrolizumab |
|---|---|
| Disease Control Rate (DCR) | 35.5 |
Collected over Throughout study duration, up to approx 80 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pembrolizumab | 26/36 (72.2%) | 9/36 (25%) | 36/36 (100%) |
| Event | Pembrolizumab |
|---|---|
| DyspneaRespiratory, thoracic and mediastinal disorders | 2/36 |
| Gastric hemorrhageGeneral disorders | 2/36 |
| Abdominal painGastrointestinal disorders | 2/36 |
| Endocrine disordersEndocrine disorders | 1/36 |
| Nervous system disordersNervous system disorders | 1/36 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/36 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/36 |
| StrokeNervous system disorders | 1/36 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/36 |
| SepsisInfections and infestations | 1/36 |
| Event | Pembrolizumab |
|---|---|
| DiarrheaGastrointestinal disorders | 13/36 |
| ConstipationGastrointestinal disorders | 12/36 |
| Abdominal PainGastrointestinal disorders | 9/36 |
| AnorexiaMetabolism and nutrition disorders | 9/36 |
| FatigueGeneral disorders | 8/36 |
| Alkaline phosphatase increasedInvestigations | 7/36 |
| Blood bilirubin increasedInvestigations | 7/36 |
| BloatingGastrointestinal disorders | 7/36 |
| Injection site reactionGeneral disorders | 7/36 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 6/36 |
| Age, Continuous(years) | Pembrolizumab |
|---|---|
| Mean | 64.3 ± 9.79 |
| Sex: Female, Male(Participants) | Pembrolizumab |
|---|---|
| Female | 10 |
| Male | 26 |
| Race (NIH/OMB)(Participants) | Pembrolizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 28 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Region of Enrollment(participants) | Pembrolizumab |
|---|---|
| United States | 36 |
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Susan E. Bates